Have you ever looked in the mirror and noticed your skin doesn't bounce back like it used to? You're not alone. As we age, our skin loses collagen, the protein that keeps it firm and youthful. The good news? RF microneedling might be just what your skin needs. This treatment works wonders for skin rejuvenation by kickstarting your body's natural collagen production. Let's talk about how it works and why it's becoming so popular.
What is RF Microneedling?
RF microneedling combines two powerful skin treatments into one. First, there's microneedling, which uses tiny needles to create small punctures in your skin. Then, there's radiofrequency (RF) energy, which heats the deeper layers of your skin. Together, they work to wake up your skin's natural healing powers.
The device used has super fine, sterile needles that create controlled punctures while delivering radiofrequency energy beneath your skin's surface. Think of it as a high-tech facial that works from the inside out. Unlike regular microneedling, the added RF energy reaches deeper layers where collagen forms, giving you better results.
How RF Microneedling Works
Your skin is smart. When it detects an injury, even a tiny one, it jumps into action to repair itself.
RF microneedling treatment takes advantage of this natural process, but in a controlled, targeted way that leads to fresher, more youthful skin.
The treatment triggers your skin's healing response without causing damage. This controlled stimulation is what makes RF microneedling so effective – it tricks your skin into thinking it needs repair, so your body produces fresh collagen right where you need it most.
Dr. Mosnaim[/caption]
Dr. Giselle Mosnaim MD MS FACAAI
Allergist
Division of Allergy and Immunology
Department of Medicine
Northshore University Health System
REMIX-1/-2 Investigator
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Chronic spontaneous urticaria is a debilitating condition significantly affecting patient quality of life and is characterized by the presence of itch, hives, and/or angioedema (swelling) lasting for greater than 6 weeks, without identifiable trigger. Second-generation H1-antihistamines at standard doses are recommended as first-line treatment for patients with chronic spontaneous urticaria, and can be up-dosed to 4 times the standard dose. However, over 50% of patients continue to have symptoms despite this therapy. Both Remibrutinib and Dupilumab are FDA-approved for the treatment of chronic spontaneous urticaria in adult patients (Remibrutinib ≥ 18 years old and Dupilumab ≥ 12 years old) who remain symptomatic despite second-generation H1-antihistamine treatment.
The RECLAIM study is an ongoing head-to-head randomized controlled trial comparing the efficacy of Remibrutinib, an oral Bruton’s tyrosine kinase inhibitor, and Dupilumab, an injectable anti-interleukin-4 and anti-interleukin-13 inhibitor, at early timepoints (4 weeks and earlier) when administered as an add-on therapy in adults with moderate to severe chronic spontaneous urticaria inadequately controlled by second-generation H1-antihistamines.
Dr. King[/caption]
Brett King, MD, PHD
Dr. King was named an American Academy of Dermatology (AAD) “Patient Care Hero”
for his work treating patients with severe alopecia areata
Dermatology Physicians of Connecticut
Fairfield, Connecticut
MedicalResearch.com: What is the background for this study? Would you briefly explain the condition of Alopecia Areata?
Response: Alopecia Areata (AA), an autoimmune form of hair loss, is common and its treatment has been revolutionized in the past ~3 years with approvals of 3 JAK inhibitors, bariticinib, ritlecitinib and deuruxolitinib. Prior to these approvals, off label treatments included the JAK inhibitors tofacitinib and ruxolitinib.
